A gene therapy founder's CSO couldn't answer one question. It killed a deal the science should have won. The founder had already cleared the BD team. Early data looked promising. Orphan designatio…
LinkedIn Content Strategy & Writing Style
Unknown
1 person tracking this creator on Viral Brain
This creator positions themselves as a high-stakes biotech strategist who bridges the lethal gap between laboratory science and pharmaceutical commercialization. Their content strategy centers on "post-mortem" narratives of failed deals, using recurring themes of manufacturing economics, patient identification, and portfolio volatility to expose the blind spots of technical founders. They are notable for their unsentimental focus on commercial viability, arguing that clinical success is irrelevant if the "cost of goods" or "diagnosed patient" data doesn't survive a corporate committee. By intersecting deep-tech empathy with cold-eyed BD diligence, they offer a rare value proposition: teaching scientists how to build programs that are not just medically sound, but "deal-proof" against shifting corporate priorities.
—
—
A gene therapy founder's CSO couldn't answer one question. It killed a deal the science should have won. The founder had already cleared the BD team. Early data looked promising. Orphan designatio…
Nail your LinkedIn strategy with ViralBrain.
Analyze and write in Unknown's style. Grow your LinkedIn to the next level.
—
—
—
—
0
A rare disease founder spent four months celebrating an FDA tailwind. He never built the thing pharma's commercial team actually asks about. Here's what happened. The FDA's new guidance dropped. He…
On Any Given Tuesday A scientist spent twenty years developing a gene therapy for children going blind. The preclinical data was strong. The clinical trial was ready to go. The pharmaceutical compan…
A rare disease patient waits 5 years for a diagnosis, then finds out nobody’s building a drug for them. Harvard Medical School and Boston Children’s just published WEST, an AI model that reads messy…
The Table and the Check A rare disease biotech got a $2.9 billion check this week. Another one auctioned off its office furniture. Same week. Same sector. Soleno built the first approved treatment…
Saw this hanging in a restaurant recently. Most people walk past it and see a beautiful photograph. I see the unofficial mascot of every rare disease patient community I've worked with for the last…